Houth Therapeutics ISIN: US44148G2049 Forum: Aktien User: abeni

@abeni 😁

https://beststocks.com/ef-hutton-maintains-buy-rating-on-hoth-therap/

🎈

... da bin ich vom Gefühl her ganz froh

After further discussions and review, both Hoth and Algorithm have determined that a definitive merger agreement cannot be reached and it is in the best interest of both companies to terminate the letter of intent and continue to operate as separate companies. "Hoth is continuing development from a position of strength and stability with over $12M on the balance sheet to carry us through more than twelve months of continued development," stated Robb Knie , CEO of Hoth. "Our Phase 2a study for patients suffering from the side effects of EGFRi treatment is underway and we believe HT-001 to be a groundbreaking treatment. I look forward to updating our shareholders as further developments of our therapeutics become available."

@Fee - EF Hutton Reiterates Buy on Hoth Therapeutics, Maintains $14 Price Target

🎈

"Today's announcement is an important milestone as the Washington University School of Medicine in St. Louis becomes our first active site for this important clinical trial. The CLEER-001 clinical trial brings us one step closer to potentially improve the quality of life for cancer patients who need this novel therapeutic." said Robb Knie, CEO of Hoth Therapeutics, Inc.

https://ir.hoththerapeutics.com/single-news-releases/

Hoth Therapeutics Announces Collaboration with First Active Clinical Site for its Phase 2 Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy

@Themenersteller: Hoth ohne U🤗

https://www.marketscreener.com/amp/quote/stock/HOTH-THERAPEUTICS-INC-54432580/news/HOTH-THERAPEUTICS-INC-Other-Events-form-8-K-43111435/

🎈

FDA is permitting the Company to proceed with its proposed use for treatment of rash and skin disorders associated with initial and repeat courses of epidermal growth factor receptor (“EGFR”) inhibitor therapy - 8k

Jetzt geh

🗯